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Objectives: To investigate whether Budesonide Easyhaler is a cost – effec-
tive treatment option in the Russian Federation, compared to Pulmicort 
Turbuhaler. MethOds: Information search was conducted in the public domain. 
Pharmacoeconomic analysis method “cost – effectiveness analysis” and direct 
cost analysis were performed. Results: The information search performed in the 
course of this study yielded outcomes of the Budesonide Easyhaler and Pulmicort 
Turbuhaler therapies in the treatment of asthma that used two effectiveness cri-
teria: improvement in lung function (peak expiratory flow – PEF) and decline the 
number of asthma exacerbations. These results are described in the publication of 
T. Vanto 2004. Then was calculated the direct cost of the various medications per 
patient. Cost analysis was conducted on the cost of basic pharmacotherapy (daily 
dose – 0,4mg), compensation costs for treatment of exacerbations, compensation 
costs for side effects and adverse reactions. The study had a time frame of one year. 
The total cost per one patient with asthma amounted to 4 727,79$ to the Budesonide 
Easyhaler group and 5 507,92$ to the Pulmicort Turbuhaler group. In the last stage, 
effectiveness parameters were obtained. They made 36 283,87$ and 47 116,55$ for 
improvement in lung function criterion, 1 477,43$ and 3 059,96$ for decline the 
number of asthma exacerbations criterion to the Easyhaler and Turbuhaler groups 
respectively. cOnclusiOns: As a result of the cost – effectiveness analysis was 
demonstrated that Budesonide Easyhaler therapy was the dominant treatment 
option, being associated with lower cost per effectiveness unit when improvement 
in lung function and decline the number of asthma exacerbations were utilized as 
the effectiveness criterion.
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Objectives: To evaluate the long-term cost-effectiveness of RMTAC (an adjunct 
pharmaceutical asthma management) vs. usual physician care clinic by using deci-
sion analytic modelling method. MethOds: A dynamic adherence asthma Markov 
cohort model was developed. The economic evaluation was based on a lifetime 
horizon and cycle length of one month, from the healthcare provider‘s (Ministry 
of Health) perspective, with the outcomes assessed in cost per QALY gained and 
cost per hospitalization averted. Probabilities of asthma control-adherence states 
from RMTAC database, costs from national sources, utilities using standard gam-
ble method on Malaysia’s asthma patients, and other inputs from secondary data 
sources were used to inform the probabilistic model, according to gender and age 
subgroups. A scenario analysis was conducted to test the structural assumption on 
follow-up visits after the final treatment visit. Results: In female subgroup, RMTAC 
management dominates the usual care by having 0.91 (95% CI 0.24 – 1.69) QALY 
gained and 0.58 (95% CI -2.30 – 6.23) hospitalization averted, at a lower cost. For male 
subgroup, the ICERs were RM10 (95% CI -RM14431 – RM8323) per QALY gained and 
RM18 (95% CI -RM35790 – RM30266) per hospitalization averted. At the willingness-
to-pay threshold of RM29000 per an additional QALY gained, the RMTAC intervention 
is likely to be cost-effective 99% and 57% of the time (for QALY and hospitalization 
outcome, respectively). The analysis was robust to assumptions of follow-up visits 
frequency and patients’ gender. cOnclusiOns: Implementing RMTAC in Malaysia 
has high probability of being more cost-effective than the usual care management 
for both male and female subgroups across all age groups. Further investigation is 
necessary to ensure that implementing this decision does not exceed the overall 
national healthcare expenditure.
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Objectives: Asthma is one of the most common chronic diseases globally. Its 
symptoms and inadequate control, which may lead to exacerbations, could impact 
on health related quality of life and health outcomes. The objective is to assess the 
cost-effectiveness of daily 5 mcg tiotropium combined with conventional treat-
ment (CT) (high-dose inhaled corticosteroids and long-acting beta2 agonists) ver-
sus CT alone for the treatment of adult patients with persistent severe asthma in 
Spain. MethOds: A Markov model was developed with 7 health states, accord-
ing to severity of exacerbations and asthma control, defined by Asthma Control 
Questionnaire (ACQ-6) results. A lifetime horizon and a Spanish National Health 
System perspective were considered, including direct medical costs (pharmaco-
logical costs and management costs for each health state). A 3% discount rate was 
applied to cost and health outcomes. Efficacy data were obtained from 205.416 and 
205.417 clinical trials, utility values from the literature, and costs from Spanish 
National databases. In order to assess the robustness of the model results, proba-
bilistic and deterministic univariate sensitivity analyses (SA) were performed 
modifying time horizon, discount rate and health state costs. Results: The model 
evaluated costs and efficacy of each alternative for severe asthma treatment, meas-
ured as quality-adjusted life year (QALY) gained. Tiotropium plus CT was asso-
ciated with 15 QALY gained and € 83,122 costs versus 14.79 and € 80,430 with CT 
alone. The incremental cost-utility ratio for tiotropium plus CT was € 12,985/QALY. 
Univariate and probabilistic SA results were robust according to the base case sce-
nario. Tiotropium therapy was a cost-effective alternative in 74.7% of simulations 
performed. cOnclusiOns: Considering the current Spanish cost-effectiveness 
Objectives: Umeclidinium/vilanterol (UMEC/VI) is a novel fixed dose combination 
of a long acting muscarinic (LAMA) and a long acting beta agonist (LABA) agents. 
The objective of this analysis was to evaluate the incremental cost-effectiveness 
ratio (ICER) of UMEC/VI compared with Tiotropium (TIO), from the Spanish National 
Health System (NHS) perspective. MethOds: A previously published linked equa-
tions cohort model based on the epidemiological longitudinal study ECLIPSE was 
used. Patients included were COPD patients with a post-bronchodilator forced expir-
atory volume in one second (FEV1) < 70% and presence of respiratory symptoms 
measured with the mMRC dyspnoea scale (mMRC > 2). Treatment effect, expressed 
as change FEV1 from baseline, was estimated from a 24 week-head-to-head phase 
III clinical trial comparing UMEC/VI with TIO and was assumed to last 52 weeks 
following treatment initiation (maximum duration of UMEC/VI clinical trials). 
Spanish utility values were derived from a published local observational study. 
Unitary healthcare costs (€ 2015) were obtained from local sources. A 3-year time 
horizon was selected and 3% discount was applied to effects and costs. Results were 
expressed as cost/quality adjusted life years (QALY). Univariate and probabilistic 
sensitivity analysis (PSA) were performed. Results: UMEC/VI produced additional 
0.03 QALY and 590€ versus TIO, leading to an ICER of 21,475€ /QALY. According to PSA, 
the probability of UMEC/VI being cost-effective was 80.3% at a willingness-to-pay 
of 30,000€ /QALY. cOnclusiOns: UMEC/VI could be considered as a cost-effective 
treatment alternative compared with TIO in symptomatic COPD patients from the 
Spanish NHS perspective.
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Objectives: Tiotropium (TIO), Spiriva Handihaler, is a well-established broncho-
dilator, LAMA (long-acting anticholinergic), for the treatment of moderate to very 
severe COPD. Clinical evidence from the SPARK trial suggests that TIO is superior to 
glycopyrronium (GLY), Seebri Breezhaler, in preventing severe exacerbations. This 
study assessed the cost-effectiveness of TIO versus GLY for Spain making use of 
this new clinical evidence. MethOds: A Markov cohort model, with GOLD II – IV 
patients, was populated with efficacy data from the UPLIFT and SPARK trials as 
well as Spanish costs, utilities and epidemiological data. Treatment efficacy was 
modelled as improvements in lung function, quality-adjusted life years and as a 
lowering of the risk of exacerbations (rate of exacerbations). Relative efficacy of 
preventing exacerbations differed between treatment cohorts based on data from 
SPARK. Health and cost outcomes were simulated over an approximate life time 
horizon, starting from an age of 65 years. Robustness of results was validated in 
deterministic and probabilistic sensitivity analyses. Results: Over the life-time 
horizon, patients treated with TIO and GLY accumulated € 41,129 and € 40,063 respec-
tively in direct costs (€ 2014). TIO generated more QALYs (7.77) compared to GLY 
(7.52). In incremental terms TIO gained 0.25 QALYs compared to GLY at an incre-
mental cost of € 1,066, resulting in a cost per QALY gained of € 4,281 (cost and health 
outcomes discounted at 3% per annum). The results were mainly driven by the 
relative risk of severe exacerbations found in SPARK (RR GLY/TIO: 1.43 CI 1.05-1.97, 
P 0.025). cOnclusiOns: The results from this study show that TIO is a highly cost-
effective treatment compared to GLY in moderate to very severe COPD. The cost per 
QALY is well-below the willingness-to-pay threshold for Spain (€ 30,000).
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Objectives: To estimate the Cost-Effectiveness of Fluticasone propionate/
Formoterol fumarate (FPF) versus Fluticasone/Salmeterol (FS) and Budesonide/
Formoterol (BF) in the treatment of adult patients with moderate to severe asthma 
from the perspective of the Society in Spain. MethOds: A Markov model was 
developed with five asthma health states: successful control, sub-optimal control, 
outpatient-managed exacerbation, inpatient-managed exacerbation, and death. 
Time horizon was set at 12 months. Weekly transition probabilities were derived 
from previous international and Spanish publications. Indirect resources utilization 
were obtained from a published Spanish study to ascertain healthcare resources 
utilization, identified as lost-workday-equivalents, and corresponding costs related 
with treatment of asthma in the year 2014. Effectiveness was expressed as qual-
ity-adjusted life years (QALY) gained. The cost-effectiveness was expressed as an 
incremental cost effectiveness ratio (ICER). Univariate and probabilistic sensitivity 
analysis (SA) were also applied. Results: FPF drug acquisition cost was lower (20% 
compared to FS and 30% compared to BF), whilst QALY of the three alternatives 
compared were very similar. Cost per patient on the FPF cohort yielded € 9,326/year, 
being the lowest price alternative: -1.5% compared to FS and -2.6% compared to BF. 
The sub-optimal control health state was the mainstay of costs (80% of total costs) 
in any of the analyzed alternatives and the scenarios. SA results confirmed the data 
from the base case scenario. cOnclusiOns: From the Spanish societal perspective 
in year 2014, FPF produced similar QALY gain at a lower cost when compared with 
FS and BF in a highly meaningful number of replications and scenarios. FPF may 
be considered a cost-effective alternative in the treatment of moderate to severe 
asthma in Spain. The cost savings were mainly due to significant FPF lower price 
acquisition costs compared to the other two alternatives.
